You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Protein Kinase Inhibitor

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Cancer Trial in Changsha (Protein Kinase Inhibitor)

Recruiting
  • Cancer
  • Protein Kinase Inhibitor
  • Changsha, Hunan, China
    Central South University
Jun 23, 2022

Hepatocellular Carcinoma Trial in Taichung (Xiang Sha Liu Jun Zi Decoction dry powder, XSLJZ Placebo)

Enrolling by invitation
  • Hepatocellular Carcinoma
  • Xiang Sha Liu Jun Zi Decoction dry powder
  • XSLJZ Placebo
  • Taichung, 西屯區, Taiwan
    China Medical University hospital
Dec 9, 2021

Neurofibromatosis 1, Neurofibroma Plexiform Trial in Shanghai (Selumetinib)

Active, not recruiting
  • Neurofibromatosis 1
  • Neurofibroma Plexiform
  • Shanghai, China
  • +1 more
Jan 13, 2023

Neurofibromatosis 1, Neurofibromatosis Type 1, NF1 Trial run by the National Cancer Institute (NCI) (AZD6244)

Active, not recruiting
  • Neurofibromatosis 1
  • +3 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center, 9000 Rockville Pi
Aug 24, 2022

Advanced Breast Cancer, Treatment-Refractory Solid Tumors, Retinoblastoma Deficiency Trial in Providence (Palbociclib Oral

Not yet recruiting
  • Advanced Breast Cancer
  • +6 more
  • Providence, Rhode Island
    Lifespan Cancer Institute
Feb 1, 2023

Advanced Malignant Solid Tumor, Metastatic Malignant Solid Tumor, Unresectable Solid Tumor Trial in United States (CDK Inhibitor

Active, not recruiting
  • Advanced Malignant Solid Neoplasm
  • +2 more
  • CDK Inhibitor AT7519
  • +3 more
  • Washington, District of Columbia
  • +5 more
Oct 18, 2022

Hepatocellular Carcinoma Non-resectable, Transarterial Chemoembolization, Tyrosine Kinase Inhibitor Trial in Chengdu (lenvatinib

Enrolling by invitation
  • Hepatocellular Carcinoma Non-resectable
  • +3 more
  • lenvatinib + sindilimab/carrelizumab
  • TACE
  • Chengdu, Sichuan, China
    West China Hospital of Sichuan University
May 23, 2022

Neurofibromatosis Type 1 Trial in Japan (Selumetinib)

Active, not recruiting
  • Neurofibromatosis Type 1
  • Minato-ku, Japan
  • +3 more
Jun 9, 2022

Lung Cancer Trial in Carlsbad, Cleveland (ISIS 3521, carboplatin, paclitaxel)

Completed
  • Lung Cancer
  • ISIS 3521
  • +2 more
  • Carlsbad, California
  • +1 more
Dec 1, 2022

Chronic Lymphocytic Leukemia, Richter Syndrome, Small Lymphocytic Lymphoma Trial in Rochester (Acalabrutinib, Durvalumab,

Recruiting
  • Chronic Lymphocytic Leukemia
  • +2 more
  • Rochester, Minnesota
    Mayo Clinic in Rochester
Jan 4, 2023

Uveal Melanoma Trial in Worldwide (LXS196, LXS196 and HDM201)

Terminated
  • Uveal Melanoma
  • New York, New York
  • +5 more
Sep 27, 2022

Blastoid Variant Mantle Cell Lymphoma, CCND1 Protein Overexpression, CD20 Positive Trial in Houston (Acalabrutinib, Venetoclax)

Recruiting
  • Blastoid Variant Mantle Cell Lymphoma
  • +8 more
  • Houston, Texas
    M D Anderson Cancer Center
Dec 5, 2022

Metastatic Pancreatic Ductal Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8 Trial

Not yet recruiting
  • Metastatic Pancreatic Ductal Adenocarcinoma
  • +3 more
  • Biopsy
  • +8 more
  • (no location specified)
Jan 13, 2023

Liver Tumors Trial in Beijing (Tislelizumab plus tyrosine kinase inhibitor)

Recruiting
  • Liver Neoplasms
  • Tislelizumab plus tyrosine kinase inhibitor
  • Beijing, Beijing, China
    302 Hospital
Sep 22, 2023

Advanced Malignant Solid Tumor, C-KIT Tyrosine Kinase Protein Overexpression, Clinical Stage IV Cutaneous Melanoma AJCC v8 Trial

Recruiting
  • Advanced Malignant Solid Neoplasm
  • +8 more
  • Imatinib Mesylate
  • Ipilimumab
  • Houston, Texas
    M D Anderson Cancer Center
Aug 1, 2022

Pancreatic Ductal Adenocarcinoma Trial (combination therapy with no MEKi, combination therapy with MEKi-HCQ, combination therapy

Not yet recruiting
  • Pancreatic Ductal Adenocarcinoma
  • combination therapy with no MEKi
  • +3 more
  • (no location specified)
Nov 29, 2022

Cyclin-dependent Kinase Inhibitor 2A on Labor-related Signals

Not yet recruiting
  • Preterm Labor
    • (no location specified)
    May 9, 2023

    Lung Tumor, NSCLC, Respiratory Tract Tumors Trial in United States (BLU-701, osimertinib, carboplatin)

    Recruiting
    • Lung Neoplasm
    • +26 more
    • Boston, Massachusetts
    • +6 more
    Jun 23, 2022

    CML Trial in Ciudad Autonoma de Buenos Aire (Discontinuing treatment with Tyrosine Kinase Inhibitor after enrolment)

    Recruiting
    • CML
    • Discontinuing treatment with Tyrosine Kinase Inhibitor after enrolment
    • Ciudad Autonoma de Buenos Aire, Ciudad Autonoma De Buenos Aires, Argentina
      FUNDALEU
    Jun 29, 2023

    Tumor Feeding Vessels Deprivation Combined With Tyrosine Kinase

    Recruiting
    • Liver Transplant
    • PVHA or TACE
    • Shanghai, Shanghai, China
      The value of tumor feeding vessels deprivation combined with tyr
    Nov 26, 2022

    Cushing Disease Trial (Fimepinostat)

    Not yet recruiting
    • Cushing Disease
    • (no location specified)
    Jul 31, 2023

    Advanced Solid Tumor, Metastatic Solid Tumor Trial (PEP07)

    Not yet recruiting
    • Advanced Solid Tumor
    • Metastatic Solid Tumor
    • (no location specified)
    Aug 1, 2023

    Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Stage III Lung

    Active, not recruiting
    • Advanced Lung Non-Squamous Non-Small Cell Carcinoma
    • +5 more
    • Sacramento, California
    • +17 more
    Aug 2, 2022

    Advanced Solid Tumors Trial in Worldwide (MSC2490484A (M3814), Fractionated RT, Cisplatin)

    Completed
    • Advanced Solid Tumors
    • MSC2490484A (M3814)
    • +2 more
    • Fresno, California
    • +25 more
    Apr 6, 2022

    Acute Myeloid Leukemia, Lymphoma, Mantle-Cell Trial (PEP07)

    Not yet recruiting
    • Acute Myeloid Leukemia
    • Lymphoma, Mantle-Cell
    • (no location specified)
    Dec 22, 2022